EyeGate Pharmaceuticals, Inc. 2018 Form 10-K Summary
Filing identity: The supplied filing is for EyeGate Pharmaceuticals, Inc., not Kiora Pharmaceuticals, Inc. It covers the fiscal year ended December 31, 2018 and compares results with 2017.
Business Context and Reporting Period
EyeGate was a clinical-stage specialty pharmaceutical company developing ophthalmic products based on its CMHA-S ocular-surface platform and EyeGate II iontophoresis delivery system. Its lead candidate, EyeGate Ocular Bandage Gel (OBG), targeted corneal epithelial defects following PRK surgery and punctate epitheliopathies. EGP-437 targeted post-cataract inflammation and pain and non-infectious anterior uveitis.
The company had 11 full-time employees, operated in one research-and-development segment, and had no approved commercial products or significant product revenue as of December 31, 2018.
Financial Metrics
| Metric | 2018 | 2017 | Change |
|---|---|---|---|
| Collaboration revenue | $1.653 million | $0.408 million | +$1.245 million |
| Research and development expense | $8.056 million | $10.330 million | -$2.275 million |
| General and administrative expense | $4.441 million | $4.636 million | -$0.195 million |
| Total operating expenses | $12.497 million | $14.967 million | -$2.470 million |
| Other income, net | $0.119 million | $(0.001) million | +$0.120 million |
| Net loss | $(10.811) million | $(13.218) million | Loss narrowed by $2.406 million |
| Basic and diluted loss per share | $(0.30) | $(0.93) | Improved |
| Cash and cash equivalents at year-end | $8.004 million | $7.806 million | +$0.198 million |
| Net cash used in operating activities | $(10.845) million | $(6.469) million | Higher use of $4.376 million |
| Net cash provided by financing activities | $11.305 million | $10.671 million | +$0.633 million |
Revenue in 2018 consisted primarily of Bausch Health Companies milestone-related collaboration revenue rather than product sales. The company had no material debt other than ordinary-course payables and capital lease obligations. Total liabilities were $5.344 million, including $2.686 million of deferred revenue and $1.210 million of contingent consideration. Stockholders’ equity was $8.936 million at year-end versus a deficit of $1.927 million in 2017, largely reflecting the 2018 equity offering and accounting changes.
Material Changes Versus the Prior Comparable Period
- R&D spending declined as EGP-437 trial activity, OBG CMC work, and generator-related activity decreased; this was partly offset by OBG PRK and PE trials and EGP-437 CMC work.
- Collaboration revenue increased because 2018 included $1.653 million of Bausch Health milestone revenue. The company adopted ASC 606 on January 1, 2018, producing a $9.5 million cumulative reduction to beginning accumulated deficit and substantially accelerating recognition of Bausch Health contract revenue.
- The company raised approximately $10.1 million net in an April 2018 public offering and received approximately $1.2 million from warrant exercises. The offering issued common stock, Series C convertible preferred stock, and warrants, creating substantial potential dilution.
- Cash remained broadly stable despite a larger operating cash burn because financing proceeds exceeded operating and investing cash uses.
- In September 2018, the company paid SentrX $250,000 for manufacturing trade secrets and know-how related to OBG; SentrX could receive up to $4.75 million in future milestones.
- Bausch Health notified EyeGate in December 2018 that it would terminate both EGP-437 license agreements effective March 14, 2019, returning the EGP-437 rights to EyeGate and eliminating the expected collaboration path.
Clinical, Regulatory, Outlook, and Risks
- OBG produced positive topline results in 2018. In a 45-subject PRK study, both OBG regimens outperformed standard care for healing at Days 3 and 4, with no observed safety concerns. In a 30-subject PE study, OBG improved symptoms significantly versus rewetting drops, also without observed safety concerns.
- EyeGate planned an FDA pre-submission meeting on March 20, 2019 regarding the de novo 510(k) strategy, clinical plan, data package, and potential submission timing for OBG. No FDA marketing clearance had been obtained.
- EGP-437 did not meet key objectives: the Phase 2b cataract-surgery trial did not achieve statistical significance on its co-primary endpoints, and the Phase 3 uveitis trial did not demonstrate non-inferiority to prednisolone acetate. Management was evaluating strategic options.
- Management expected continued significant expenses and increasing operating losses. Based on year-end cash, it estimated that planned operations could be funded through February 28, 2020, but stated that additional equity, debt, grants, licensing, or collaboration funding would be required.
- The auditor’s report included an explanatory paragraph regarding substantial doubt about the company’s ability to continue as a going concern. The financial statements contained no adjustments for a possible inability to continue operations.
- Key risks included dependence on OBG, regulatory approval uncertainty, clinical-trial failure, limited manufacturing capacity and lack of binding commercial supply arrangements, reliance on third parties, intellectual-property challenges, reimbursement uncertainty, competition, future dilution, and possible Nasdaq delisting for failure to satisfy the $1.00 minimum bid-price requirement.
- At December 31, 2018, the company had 40.844 million outstanding warrants, 2.076 million stock options, and Series C preferred stock convertible into 12.788 million common shares, all excluded from diluted loss per share because they were anti-dilutive.
Most Important Facts for Investors to Verify
- Confirm that the intended issuer is EyeGate Pharmaceuticals rather than Kiora Pharmaceuticals.
- Verify the company’s post-filing Nasdaq listing status and resolution of the minimum bid-price deficiency.
- Assess actual cash runway, subsequent financing activity, and whether additional capital was raised on terms that materially diluted shareholders.
- Review the FDA outcome and submission timing for the OBG de novo application and any additional clinical requirements.
- Determine the post-termination strategy, costs, and partnering status for EGP-437.
- Reconcile collaboration revenue recognized under ASC 606 with cash received, remaining deferred revenue, and the effect of Bausch Health’s termination.
- Evaluate potential dilution from warrants, preferred-stock conversion rights, options, and restricted shares.
- Review subsequent events for changes to the going-concern assessment, manufacturing arrangements, license obligations, and litigation or regulatory matters.